Articles published by Agendia

Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium

November 25, 2025

From Agendia

Via Business Wire

Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium

November 04, 2025

From Agendia

Via Business Wire

Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint® and BluePrint® for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024

December 12, 2024

From Agendia

Via Business Wire

Agendia Announces New Data Assessing the Immune Active State in HR+/HER2- Early-Stage Breast Cancer at 2024 ASCO

May 31, 2024

From Agendia

Via Business Wire

Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care

May 24, 2024

From Agendia

Via Business Wire

Agendia Level 1B Evidence Shows MammaPrint® is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients

December 08, 2022

From Agendia

Via Business Wire

Agendia Appoints Farida Peters-Abbadi as Vice President of Marketing

April 04, 2022

From Agendia

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.